Speeding up and bringing down the cost of clinical trials would be a huge boon to pharma companies and patients alike.
San Francisco-based startup Unlearn.AI says it has developed proprietary technology that may help accomplish just that. On Monday the company announced it raised $12 million from investors who believe it stands out among the crowded field of tech outfits looking to tap into the huge amount of money spent conducting such studies.
